The inhibition of Ezrin blocked HER2 signaling and caused a PKCα-mediated internalization and degradation of HER2, inhibiting proliferation and promoting apoptosis in HER2-positive breast cancer cells [131]. Here, ERBB2 is linked to breast carcinoma.